Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Complete Title: Larotrectinib to enhance RAI avidity in patients with differentiated thyroid cancer harboring NTRK fusions
Trial Phase: II
Investigator: Tyler Ketterl
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Keywords:
- Pediatric Cancers, Miscellaneous; Thyroid Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.